Acute tumor lysis syndrome complicating fludarabine treatment of prolymphocytic leukemia.
Tumor lysis syndrome rarely occurs during chemotherapy treatment of indolent lymphoid tumors. This report describes for the first time a case of acute tumor lysis syndrome complicating fludarabine treatment of prolymphocytic leukemia. In this particular case the patient had an unexpectedly rapid response to fludarabine 15 days after initiation of the first chemotherapy cycle, which was subsequently complicated by the development of tumor lysis syndrome. Until more data are known concerning fludarabine treatment of prolymphocytic leukemia, cautious monitoring of patients treated with fludarabine should be undertaken, even after completion of the chemotherapy course.
Cannon
L M
LM
Department of Medicine, Danbury Hospital, Yale University School of Medicine.
Spilove
L
L
Rhodes
R
R
Garfinkel
H
H
Pezzimenti
J
J
D000208:Acute Disease; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D015463:Leukemia, Prolymphocytic / Q000188:drug therapy* / Q000503:physiopathology; D015275:Tumor Lysis Syndrome / Q000209:etiology* / Q000503:physiopathology; D014740:Vidarabine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000970:Antineoplastic Agents; D014740:Vidarabine; C024352:fludarabine